Education
About Us
Working with TipRanks
Follow Us
BioNexus Gene Lab Corp (BGLC)
NASDAQ:BGLC
Total Valuation
BioNexus Gene Lab Corp has a market cap or net worth of $4.80M. The enterprise value is ―.
Market Cap$4.80M
Enterprise Value―
Share Statistics
BioNexus Gene Lab Corp has 1,796,766 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,796,766
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioNexus Gene Lab Corp’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -26.67%.
Return on Equity (ROE)-0.27
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-26.67%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee325.69K
Profits Per Employee-87.63K
Employee Count30
Asset Turnover0.86
Inventory Turnover7.42
Valuation Ratios
The current PE Ratio of BioNexus Gene Lab Corp is -3.20. BioNexus Gene Lab Corp’s PEG ratio is >-0.01.
PE Ratio-3.20
PS Ratio0.55
PB Ratio0.87
Price to Fair Value0.87
Price to FCF-5.80
Price to Operating Cash Flow-6.46
PEG Ratio>-0.01
Income Statement
In the last 12 months, BioNexus Gene Lab Corp had revenue of 9.77M and earned -2.63M in profits. Earnings per share was -0.17.
Revenue9.77M
Gross Profit1.33M
Operating Income-2.59M
Pretax Income-2.61M
Net Income-2.63M
EBITDA-2.49M
Earnings Per Share (EPS)-0.17
Cash Flow
In the last 12 months, operating cash flow was -2.42M and capital expenditures -223.90K, giving a free cash flow of -2.63M billion.
Operating Cash Flow-2.42M
Free Cash Flow-2.63M
Free Cash Flow per Share-1.47
Dividends & Yields
BioNexus Gene Lab Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change-52.06%
50-Day Moving Average3.11
200-Day Moving Average3.67
Relative Strength Index (RSI)50.16
Average Volume (3m)1.25M
Important Dates
BioNexus Gene Lab Corp upcoming earnings date is ―, TBA Not Confirmed.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
BioNexus Gene Lab Corp as a current ratio of 4.93, with Debt / Equity ratio of 2.41%
Current Ratio4.93
Quick Ratio4.24
Debt to Market Cap0.00
Net Debt to EBITDA2.33
Interest Coverage Ratio-186.20
Taxes
In the past 12 months, BioNexus Gene Lab Corp has paid 21.53K in taxes.
Income Tax21.53K
Effective Tax Rate>-0.01
Enterprise Valuation
BioNexus Gene Lab Corp EV to EBITDA ratio is -1.05, with an EV/FCF ratio of -1.80.
EV to Sales0.27
EV to EBITDA-1.05
EV to Free Cash Flow-1.80
EV to Operating Cash Flow-2.01
Balance Sheet
BioNexus Gene Lab Corp has $4.14M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$3.91M billion.
Cash & Marketable Securities$4.14M
Total Debt$0.00
Net Cash-$3.91M
Net Cash Per Share-$2.18
Tangible Book Value Per Share$0.61
Margins
Gross margin is 13.25%, with operating margin of -26.54%, and net profit margin of -26.91%.
Gross Margin13.25%
Operating Margin-26.54%
Pretax Margin-26.69%
Net Profit Margin-26.91%
EBITDA Margin-25.43%
EBIT Margin-26.54%
Analyst Forecast
The average price target for BioNexus Gene Lab Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―